View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with sample
  1. News
November 5, 2018updated 29 Nov 2018 7:29am

Announcing ‘The Return of Outsourcing Week’ on Clinical Trials Arena

Throughout this week, CTA will spotlight the ever-changing outsourcing landscape

As Arena International’s Outsourcing in Clinical Trials New England conference gets underway this week in Boston, Massachusetts, Clinical Trials Arena will highlight all matters clinical outsourcing. Only months after our last focus on outsourcing clinical trials, due to popular demand, CTA will once more draw attention to the most pressing concerns facing industry professionals.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Be sure to visit us tomorrow when James Sherley, Founder and Director of Asymmetrex, exposes a problem that is crippling progress in stem cell medicine. On Wednesday, another CTA regular, Ken Getz from Tufts CSDD examines why the sponsor-CRO dynamic often falls short of expectations.

Later in the week, Lisa Henry, Manager of Clinical Research at Cordis, discusses the merits of clinical trial outsourcing models. And lastly, Daria Wicks, Director of Clinical Operations at Vericel Corporation, emphasizes the importance of clear communication between sponsors and CROs alike. So as you can tell, a deluge of topics will be explored on CTA, so be sure not to miss out this week!

In the meantime, catch up on our last Outsourcing Week in May where we featured some of the industry’s most prominent experts… (click on the headline to finish reading).

Industry Viewpoints: Adopting a Data-Driven Approach to Monitoring

For years, variants of Risk-Based Monitoring (RBM) have been implemented within sponsor organizations to carry out their data management activities. With all the rage these days centered on how innovative technologies can disrupt study processes, questions are abound as to what impact that will have on the way companies collect patient data.

In the case of RBM in particular, with machine learning and AI coming to the fore, will the industry need a rethink on how it identifies risk in clinical trials?

In this Industry Viewpoint, CTA Editor Henry Kerali sits down with Dr Craig Elliott, who’s the Global Head of Operations at Clintec International. An expert on technological advancements, Elliott explains why the industry needs to hit the reset button on RBM and adopt what he calls a ‘data-driven’ approach.

Disruptive Structural Change in the CRO Landscape

The announced acquisition of Parexel in May 2017 by private equity firm Pamplona Capital Management represents a denouement for the top four market-leading contract clinical research organizations (CROs). Quintiles, Covance, Parexel and PPD have each now experienced a change of ownership. The owners are strategic partners, well-positioned within the broader health care and life sciences arena, and private equity investors with considerable capital and broad life sciences portfolios. In all cases, the acquiring companies are not clinical research insiders.

Industry Viewpoints: The Role of Imaging Biomarkers in Clinical Trials

The use of biomarkers in clinical trials can aid operational efficiencies in drug development that as of yet, haven’t been fully realized – arguably, it must be said. But how can biomarkers best be leveraged to reduce timelines and altogether bring drugs faster to market?

In this Industry Viewpoint, Irene Mayorga Ruiz of QUIBIM sits down with Henry Kerali to discuss the importance of biomarkers. An experienced professional, Ruiz is a biomedical engineer who specializes in obtaining imaging biomarkers from medical images with treatment response value. Here, she explains how biomarkers can be incorporated into clinical trials and be fully maximized.

5 Industry Trends to Impact Clinical Outsourcing

We all love trends; fashion trends, music trends, twitter trends, you name it. In clinical trials it is no different – we love our trends. Be it patient centricity, risk-based monitoring, digitization, adaptive trials or analytics. However, we sometimes fail to see and plan for the impact these trends can have on the way we outsource our work. Below we will look at five of the current biggest clinical trial trends and see how each may impact clinical outsourcing decisions, and potentially create trends of their own.

Industry Viewpoints: The Pivotal Role of Skilled and Experienced Data Managers in Clinical Trials

If one studied the role of data manager as it is today and compared it to what the role entailed in, say, the 1970s, then what’s irrefutable is how the role has markedly changed over the years. Whereas before you had trial master files (TMFs), now you have electronic TMFs. Before you had patient reported outcomes (PROs), and now things have gone digital with ePROs.

As technologies advance, so too does the industry – no matter how seemingly slow it embraces change! But how will the industry, and more specifically, data managers adapt to the technological advances that lie in wait?

In this Industry Viewpoint, CTA Editor Henry Kerali sits down with Dr Raphalea Schnurbus, who’s the Clinical Solutions Director at OPIS. Here, she explains how data managers, from sponsors and CROs alike, must stay on their toes as the industry readies itself for the next technological paradigm.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU